BioWorld

July 29, 2004

Cell Therapeutics Adds To Cash With $42.8M Offering

Laden with the expense of pivotal trials, Cell Therapeutics Inc. raised $42.8 million to give it the reserves to last through 2005. (BioWorld Today) Read More

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

MannKind IPO Prices Within Range; Shares Close Higher

New BioDefense Guide Released With 37 Company Success Stories

Lexicon, Takeda In Agreement For High Blood Pressure Drugs

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...